Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial.
CONCLUSIONS: Fractures affected 8.8% of placebo-treated patients within five years after an ischemic stroke or TIA. Pioglitazone increased the absolute fracture risk by 1.6%-4.9% and the relative risk by 47-60%, depending on fracture classification. Our analysis suggests that treatments to improve bone health and prevent falls may help optimize the risk/benefit ratio for pioglitazone.
PMID: 27935736 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN, IRIS Trial Investigators Tags: J Clin Endocrinol Metab Source Type: research
More News: Actos | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Clinical Trials | Diabetes | Endocrinology | Heart | Insulin | Ischemic Stroke | Orthopaedics | Stroke | Women